toxicities associated with parp inhibitors in ovarian cancer
Published 7 years ago • 99 plays • Length 2:31Download video MP4
Download video MP3
Similar videos
-
2:15
toxicities associated with rucaparib for the treatment of ovarian cancer
-
3:05
managing parp inhibitor toxicities in ovarian cancer
-
1:36
dr. coleman discusses the toxicities associated with rucaparib in patients with ovarian cancer
-
1:11
solo3 highlights toxicities with olaparib in ovarian cancer
-
2:30
dr. matulonis on toxicities with parp inhibitors in ovarian cancer
-
1:27
parp inhibition improves outcomes in patients with brca-mutated ovarian cancer
-
1:56
parp inhibitor costs give patients with ovarian cancer financial toxicity
-
1:11
dr. o'malley on toxicity profiles of parp inhibitors in ovarian cancer
-
2:02
dr. konecny on resistance to parp inhibitors in ovarian cancer
-
3:05
an overview of parp inhibitors in ovarian cancer
-
1:54
dr. matulonis on toxicities with olaparib for patients with ovarian cancer
-
1:07
challenges with parp inhibitors in ovarian cancer
-
1:58
parp inhibitor combinations and future of ovarian cancer
-
2:36
managing toxicities in advanced ovarian cancer
-
59:14
parp inhibitors in ovarian cancer: clinical updates from sgo 2023
-
2:18
parp inhibition in recurrent ovarian cancer
-
8:03
parp inhibitors in ovarian cancer: safety profile
-
3:09
the promising potential of parp inhibitors in ovarian cancer
-
1:29:06
the advanced ovarian cancer treatment palette: candid conversations on parp inhibitors